Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas

US7517880B2 · kind B2 · utility

Assignee

• Bayer Pharmaceuticals Corporation · US

Inventors

• Scott C. Miller · Longmont, US
• Martin Osterhout · Raleigh, US
• Jacques Dumas · Neuilly-Plaisance, FR
• Uday Khire · Hamden, US
• Timothy B. Lowinger · Carlisle, US
• William Scott · Guilford, US
• Roger Smith · Madison, US
• Jill Wood · Hampton, US
• David Gunn · Waukegan, US
• Holia Hatoum-Mokdad · Hamden, US
• Marell Rodriguez · Guilford, US
• Robert Sibley · North Haven, US
• Ming Wang · Montgomery, US
• Tiffany Turner · Pittsburgh, US
• Catherine Brennan · Durham, US

Key dates

• Filing date: Feb 1, 2002
• Grant date: Apr 14, 2009
• Expiry date: Nov 1, 2022

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.